AVEO Pharmaceuticals, Inc. (AVEO) Receives $1.96 Average Target Price from Brokerages

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has received a consensus recommendation of “Hold” from the nine brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $1.96.

A number of analysts recently issued reports on AVEO shares. Piper Jaffray Companies reiterated an “overweight” rating and set a $3.00 price objective (down from $5.00) on shares of AVEO Pharmaceuticals in a research note on Thursday, January 31st. Zacks Investment Research upgraded AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price objective on the stock in a research note on Tuesday, March 19th. B. Riley reiterated a “neutral” rating and set a $1.00 price objective (down from $5.00) on shares of AVEO Pharmaceuticals in a research note on Monday, February 4th. BidaskClub upgraded AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 15th. Finally, National Securities started coverage on AVEO Pharmaceuticals in a research report on Thursday, March 28th. They set a “sell” rating for the company.

In other AVEO Pharmaceuticals news, major shareholder Equity Opportunities Fu Growth bought 4,347,827 shares of AVEO Pharmaceuticals stock in a transaction that occurred on Monday, April 8th. The stock was acquired at an average cost of $1.14 per share, for a total transaction of $4,956,522.78. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 4.40% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Two Sigma Securities LLC purchased a new position in shares of AVEO Pharmaceuticals in the 4th quarter worth about $28,000. Chicago Equity Partners LLC purchased a new position in shares of AVEO Pharmaceuticals in the 4th quarter worth about $32,000. Albion Financial Group UT purchased a new position in shares of AVEO Pharmaceuticals in the 4th quarter worth about $38,000. Two Sigma Advisers LP boosted its holdings in shares of AVEO Pharmaceuticals by 7.2% in the 4th quarter. Two Sigma Advisers LP now owns 422,000 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 28,500 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of AVEO Pharmaceuticals by 3.0% in the 4th quarter. Northern Trust Corp now owns 1,175,604 shares of the biopharmaceutical company’s stock worth $1,882,000 after purchasing an additional 34,164 shares in the last quarter. Hedge funds and other institutional investors own 30.92% of the company’s stock.

Shares of AVEO traded down $0.01 during mid-day trading on Friday, hitting $0.90. The stock had a trading volume of 42,876 shares, compared to its average volume of 6,424,472. The firm has a market cap of $149.52 million, a PE ratio of -4.74 and a beta of 1.21. AVEO Pharmaceuticals has a 52 week low of $0.49 and a 52 week high of $3.59.

AVEO Pharmaceuticals (NASDAQ:AVEO) last released its quarterly earnings data on Thursday, March 14th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.03. The company had revenue of $1.48 million for the quarter, compared to the consensus estimate of $2.48 million. On average, equities analysts forecast that AVEO Pharmaceuticals will post -0.16 EPS for the current year.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Further Reading: How are dividend achievers different from dividend aristocrats?

Analyst Recommendations for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.